# Laboratory Corporation of America Holdings – Consensus ‘buy’ rating and 12.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/laboratory-corporation-of-america-holdings-consensus-buy-rating-and-12.8-upside-potential/4121134895
- Published: 2023-12-01T12:52:13+00:00
- Author: Charlotte Edwards

**Laboratory Corporation of America Holdings** which can be found using ticker (
LH) now have 13 analysts in total covering the stock. The consensus rating is pointing
to ‘buy’. The target price High/Low ranges between $270.00 and $210.00 calculating
the average target price we see $241.54. Given that the stocks previous close was
at $214.09 this now indicates there is a potential upside of 12.8%. It’s also worth
noting that there is a 50 day moving average of $204.86 and the 200 day moving average
is $202.32. The total market capitalization for the company now stands at 18.42B.
The stock price for the company is currently $216.91 USD

 The potential market cap would be $20,776,861,492 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 22.32, revenue per share of $171.07
and a 5.33% return on assets.

Laboratory Corporation of America Holdings is a global life sciences company. The
Company provides information to help doctors, hospitals, pharmaceutical companies,
researchers, and patients make decisions. The Company’s segments include Labcorp
Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent
clinical laboratory business. It offers a menu of frequently requested and specialty
diagnostic tests through an integrated network of primary and specialty laboratories
across the United States. In addition to diagnostic testing along with occupational
and wellness testing for employers and forensic DNA analysis, Dx segment also offers
a range of other testing services. The DD segment is a contract research organizations
business that provides end-to-end drug development services. The DD segment provides
these services predominantly to pharmaceutical, biotechnology and medical device
companies across the world. It serves clients in more than 100 countries.

Share on: